secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001193125-26-019520
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones
--------------------------------------------------------------------------------

- Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.
- Janux responsible for preclinical through IND; BMS handles later development and commercialization.
- Tiered royalties on global net sales: high-single to low-double digit percentages.
- Collaboration validates Janux's TRACTr/TRACIr/ARM platforms for solid tumor oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/0001193125-26-019520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/janx-20260121.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-019520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer